Baird analyst David Rescott raised the firm’s price target on Inspire Medical (INSP) to $252 from $240 and keeps an Outperform rating on the shares. The firm said they remain a best-in-class idea after the company delivered another revenue/EPS beat/raise with +33% revenue growth, 7% OM, and confirmed FY25 CNS revenue growth estimates.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP: